All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III studyDavid R. Nelson, Eric Lawitz, Paul J. Pockros et al.|Hepatology|2015Cited by 689
Lethality of PAK3 and SGK2 shRNAs to Human Papillomavirus Positive Cervical Cancer Cells Is Independent of PAK3 and SGK2 KnockdownNannan Zhou, Fiona McPhee|PLoS ONE|2015Cited by 9